Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion

Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion

Cardiac adverse effects are among the leading causes of the discontinuation of clinical trials and the withdrawal of drugs from the market. The novel concept of ‘hidden cardiotoxicity’ is defined as cardiotoxicity of a drug that manifests in the diseased (e.g. ischemic/reperfused...

Full description

Bibliographic Details
Main Authors: Gábor B. Brenner, András Makkos, Csilla Terézia Nagy, Zsófia Onódi, Nabil V. Sayour, Tamás G. Gergely, Bernadett Kiss, Anikó Görbe, Éva Sághy, Zoltán S. Zádori, Bernadette Lázár, Tamás Baranyai, Richárd S. Varga, Zoltán Husti, András Varró, László Tóthfalusi, Rainer Schulz, István Baczkó, Zoltán Giricz, Péter Ferdinandy
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Cells
Subjects:
cardiotoxicity
cox-2
electrophysiology
safety testing
arrhythmia
vioxx
ischemic conditioning
reperfusion injury
hiddentox
pharmacovigilance
Online Access:https://www.mdpi.com/2073-4409/9/3/551

Internet

https://www.mdpi.com/2073-4409/9/3/551

Similar Items